: Currently priced around $7.29 with projected sales growth of over 77% for the year.
These companies are considered "cheap" due to low price-to-earnings (P/E) ratios relative to their historical averages or the broader sector. cheap biotech stocks to buy
: Trading at roughly 15 times earnings with double-digit increases in revenue and low debt. : Currently priced around $7
: A clinical-stage biotech developing heart disease therapies with positive Phase 2 data and a mean target price suggesting over 600% upside. cheap biotech stocks to buy
: A high-risk, high-reward mRNA play with major Phase 2 study results for cystic fibrosis expected in the first half of 2026.